Joan Genescà Ferrer Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine. Institutions of which they are part Head of group Liver Diseases Vall Hebron Institut de Recerca Hepatologia General Hospital Twitter Orcid Email Joan Genescà Ferrer Twitter Orcid Email Institutions of which they are part Head of group Liver Diseases Vall Hebron Institut de Recerca Hepatologia General Hospital Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.
Projects Targeted biodegradable nanoparticles of simvastatin as new therapeutic tool for chronic liver disease IP: Joan Genescà Ferrer Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 80598 Reference: CD19/00049 Duration: 01/01/2020 - 18/04/2022 BIODEGRADABLE NANOPARTICLES OF SIMVASTATIN AS NEW THERAPEUTIC TOOL FOR CHRONIC LIVER DISEASE (NANOSIM) IP: Joan Genescà Ferrer Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 199952 Reference: ISCIII/EURONANOMED/2018/NANOSIM/DUP Duration: 22/10/2018 - 22/10/2018 BIODEGRADABLE NANOPARTICLES OF SIMVASTATIN AS NEW THERAPEUTIC TOOL FOR CHRONIC LIVER DISEASE (NANOSIM) IP: Joan Genescà Ferrer Collaborators: Maria Nieves Martell Pérez-Alcalde, Diana Fernandes de Rafael Funding agency: Instituto de Salud Carlos III Funding: 199946.45 Reference: AC18/00033 Duration: 01/01/2019 - 31/12/2022 De la sencillez en el diagnóstico (no masivo) y seguimiento de la enfermedad hepática crónica avanzada a los complejos mecanismos terapéuticos de las estatinas en modelos animales. IP: Joan Genescà Ferrer Collaborators: Immaculada Raurell Saborit, Torrens Buscató, Maria Margarita, Ares Aurora Villagrasa Vilella, Mònica Pons Delgado Funding agency: Instituto de Salud Carlos III Funding: 196020 Reference: PI18/00947 Duration: 01/01/2019 - 30/06/2023 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Page 5 … Next page › Last page »